Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Los Angeles, CA
Treatments:ChemotherapyHospital:University of Southern California Norris Comprehensive Cancer Center
Drugs:Journal:Link
Date:Aug 2013

Description:

Patients:
This phase 3 study involved advanced castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A had 496 patients with a median age of 69 years. There were 498 patients in group B with a median age of 69 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel.

Patients in group B were treated with docetaxel and the biologic therapy agent called atrasentan, which is an inhibitor of the endothelin receptor and may inhibit cancer metastases.

Toxicities:
There were seven treatment-related deaths in group A due to respiratory failure, infection, heart failure, and skin toxicity.

There were three treatment-related deaths in group B due to bleeding and infection.

Results:
The median overall survival in groups A and B was 17.6 and 17.8 months, respectively.

Support:
This study was partially supported by Sanofi-Aventis and Abbott Laboratories.

Correspondence: Dr. David I Quinn; email: [email protected]



Back